Divergent mutational processes distinguish hypoxic and normoxic tumours
Authors:
- Vinayak BhandariVBVinayak Bhandari
- Constance H. LiCLConstance H. Li
- Robert G. BristowRBRobert G. Bristow
- Paul C. BoutrosPBPaul C. Boutros
- On Behalf Of The Pcawg NetworkONOn Behalf Of The Pcawg Network
Preprint
- 28 January 2019
- preprint
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 531996
Abstract
Many primary tumours have low levels of molecular oxygen (hypoxia). Hypoxic tumours are more likely to metastasize to distant sites and respond poorly to multiple therapies. Surprisingly, then, the pan-cancer molecular hallmarks of tumour hypoxia remain poorly understood, with limited understanding of its associations with specific mutational processes, non-coding driver genes and evolutionary features. To fill this gap, we quantified hypoxia in 1,188 tumours spanning 27 cancer types. We show that elevated hypoxia is associated with increased mutational load across cancers, irrespective of the underlying mutational class. The proportion of mutations attributed to several mutational signatures of unknown aetiology are directly associated with the level of hypoxia, suggesting underlying mutational processes for these signatures. At the gene level, driver mutations in TP53, MYC and PTEN are enriched in tumours with high hypoxia, and mutations in PTEN interact with hypoxia to direct the evolutionary trajectory of tumours. Overall, this work demonstrates that hypoxia plays a critical role in shaping the genomic landscape of cancer.Keywords
All Related Versions
- Published version: Nature Communications, 11 (1), 1.
This publication has 46 references indexed in Scilit:
- The Clinical Significance of Hypoxia in Human CancersSeminars in Nuclear Medicine, 2015
- Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy ResponseClinical Cancer Research, 2013
- The tumor microenvironmentSurgical Oncology, 2012
- Effects of hypoxia and HIFs on cancer metabolismInternational Journal of Hematology, 2012
- Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder CarcinomaJournal of Clinical Oncology, 2010
- The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5Journal of Clinical Investigation, 2010
- HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancerRadiotherapy and Oncology, 2010
- Exploiting tumour hypoxia in cancer treatmentNature Reviews Cancer, 2004
- Antiangiogenic therapy and tumor progressionCancer Cell, 2004
- Treatment Resistance of Solid TumorsMedical Oncology, 2001